S
LE is characterized by the production of autoantibodies, which places B cells centrally in SLE etiology. Autoreactive B cells are censored through tolerance checkpoints, which can be overcome by the convergence of Toll-like receptor (TLR), cytokine and/ or co-receptor malfunction thereby leading to the expansion of pathogenic B cells 1 . Genome-wide association studies (GWAS) of SLE have revealed a striking concentration of disease-susceptibility alleles in the B cell antigen receptor (BCR) signaling and B cell costimulation pathways 2, 3 . Experimental evidence supports a role for both germinal center reactions and extrafollicular B cell activation and differentiation pathways in the generation of autoantibodies and autoimmunity in mice 4 . We have shown previously that SLE is characterized by the expansion of naive B cells with an activated phenotype 5 and a distinct subset of isotype-switched B cells that harbor somatic hypermutation but lack expression of CD27, a universal marker of memory B cells, termed DN2 (CD27 . DN2 cells are poised to differentiate into antibody-secreting cells (ASCs) through unregulated TLR7 and interleukin 21 (IL-21) stimulation 6 and bear resemblance to murine age-associated B cells (ABCs). ABCs require TLR7 signaling for expansion, express CD11c and T-BET and are enriched in BCRencoding autoantibodies [7] [8] [9] . TLR signaling can be modulated by type I interferon (IFN) 10 , which is prevalent in SLE, and may epigenetically influence disease flares 11, 12 . The strong linkage of DN2 cells and related subsets to TLR-driven pathways suggests that a unique combination of stimuli influences the fate of autoreactive B cells.
Altered epigenetic states, including DNA hypomethylation in B cells 11 and disease-associated peaks of chromatin accessibility in naive B cells 13 , have been described for SLE and other autoimmune diseases 14, 15 , suggesting that epigenetic differences may influence B cell responses. Therefore, we examined and compared the DNA methylation epigenomes, chromatin accessibility profiles and transcriptomes of human B cells from healthy controls and subjects with SLE, analyzing cell subsets that represent resting, activated and memory compartments. A hierarchy in B cell differentiation and multiple SLE disease signatures that already manifested in naive B cells 13 were found to persist throughout B cell differentiation. Transcription factor networks that were altered in subjects with SLE converged on signaling networks and revealed external environmental cues that contribute to the expansion of pathogenic B cell subsets. Thus, the SLE environment predisposes B cells to a pathogenic phenotype that is epigenetically propagated through B cell differentiation and primes differentiation of extrafollicular naive B cells into ASCs.
Results
Molecular relationships of B cell subsets in subjects with SLE and healthy controls. To characterize the epigenetic relationships among human B cell populations in subjects with SLE, a cohort of African-American females (9 subjects with SLE and 12 healthy controls) was recruited (Supplementary Table 1 ). Peripheral B cells can be divided into subtypes that represent naive cells, activated stages and isotype-switched memory cells 5, 16, 17 . Five circulating human B cell subsets were isolated by flow cytometry from each subject using MitoTracker Green dye (MTG) and phenotypic markers 5, 17 : resting naive (CD19 To address this, we determined the DNA methylomes, chromatin accessibility profiles and transcriptomes from five human B cell subsets, including a newly defined effector B cell subset, from subjects with SLE and healthy controls. Our data define a differentiation hierarchy for the subsets and elucidate the epigenetic and transcriptional differences between effector and memory B cells. Importantly, an SLE molecular signature was already established in resting naive cells and was dominated by enrichment of accessible chromatin in motifs for AP-1 and EGR transcription factors. Together, these factors acted in synergy with T-BET to shape the epigenome of expanded SLE effector B cell subsets. Thus, our data define the molecular foundation of pathogenic B cell dysfunction in SLE.
and activated naive populations, both characterized by a CXCR5 − phenotype, are expanded in individuals with SLE experiencing flares and are potential disease drivers 5, 6 . Consistent with results from previous cohorts 5, 6 , subjects with SLE had highly significant expansion of the activated naive and DN2 B cell populations, smaller but significant increases in the T3 B cell population and a subtle decrease in the population of resting naive B cells ( Supplementary Fig. 1 ).
An integrated approach was taken that assayed DNA methylation status by reduced-representation bisulfite sequencing (RRBS) 18 and the effect of epigenetic programs on the accessibility of chromatin, as determined by assay for transposase-accessible chromatin using sequencing (ATAC-seq) 13, 19 ( Supplementary Fig. 2 ). The phenotypic readout for epigenetic programs was assessed by RNA sequencing (RNA-seq). Differentially methylated loci (DMLs), differentially accessible regions (DARs) and differentially expressed genes (DEGs) were determined in comparisons of each cell type according to SLE disease status. Principal-component analysis (PCA) of all DML indicated a linear separation of cell types that progressed from resting naive to isotype-switched memory B cells in both subjects with SLE and healthy controls (Fig. 1a) . One major epigenetic feature of B cell differentiation is the targeted and progressive global hypomethylation that occurs as B cells differentiate to ASCs 18, 20 , suggesting that the changes observed by PCA may represent a differentiation hierarchy. Indeed, we observed the same phenomena with clear progressive loss of DNA methylation across these cell subsets (Fig. 1b) . A phylogenetic analysis was performed using the DMLs identified through comparison of all cell types including ASCs, such that the beginning and differentiation end points were represented. For both subjects with SLE and healthy controls, activated naive and T3 B cells were much more similar to resting naive B cells, whereas DN2 and isotype-switched memory B cells were closely related to ASCs (Fig. 1c) . Thus, DNA methylation changes separate the various cell subsets and are indicative of a hierarchical relationship.
PCA of DARs and DEGs indicated that there was a progression from resting naive cells through T3, activated naive and isotypeswitched memory to DN2 cells. Whereas the DNA methylation analysis separated the cell types along both principal components, chromatin accessibility and gene expression PCA identified SLE B cells as distinct from B cells from healthy controls with principal component 1 (PC1) separating the populations by disease status and PC2 separating the populations by cell types (Fig. 1a) . For phylogenetic analysis of chromatin accessibility data, promoters and distal elements were considered separately as the latter have been shown to better separate cell types 21, 22 . Accessible promoters had a small overall phylogenetic distance between cell types in SLE and control samples, indicating similar promoter accessibility architecture, although DN2 and isotype-switched memory cells were closer in SLE samples than in healthy controls (Fig. 1c) . In contrast, when considering accessibility at distal elements, an expanded phylogenetic distance was observed, indicating that cis elements such as enhancers are distinct between SLE and control cell types. Similarly to previously reported data 5, 6 , analysis of the RNA-seq, ATAC-seq and RRBS data indicated that DN2 cells were most closely related to ASCs by phylogenetic tree position and distance (Fig. 1c) . As with the accessibility data, the transcriptomes of DN2 and activated naive cells showed a much closer relationship in SLE samples than in control samples, a finding that was supported by fewer DARs and DEGs in comparison of these populations in SLE samples than in control HC samples ( Supplementary Fig. 3 ). Thus, distinct epigenomes differentiate critical B cell subsets in subjects with SLE and healthy controls.
Progressive upregulation of the B cell differentiation transcriptional program. To better understand the phenotypic relationships of the cell subsets, the transcriptional programs were analyzed using gene set enrichment analysis (GSEA) 23 comparing B cell subsets from healthy controls and subjects with SLE to the respective resting naive B cells. Across cell subsets, a progressive enrichment was observed in gene sets associated with metabolism (for example, ALDOA), cell cycle (E2F1), unfolded protein response (UPR; XBP1) and activated B cells (ZBTB32) 24 as well as genes expressed in plasma cells (PRDM1 and SLAMF7) (Fig. 1d,e and Supplementary  Fig. 3 ). The overall expression levels of the gene sets were increased in T3 and activated naive cells and peaked in isotype-switched memory and DN2 cells. For example, consistent with the transcriptional upregulation of PRDM1, the PRDM1 promoter demonstrated increased accessibility and a decrease in DNA methylation that was most pronounced in DN2 and isotype-switched memory B cells. Additionally, transcriptional activity, as well as promoter and distal element accessibility, progressively increased at the SLAMF7 and XBP1 loci. Together, these data provide epigenetic evidence for progressive upregulation of genes associated with B cell and plasma cell differentiation and a differentiation hierarchy among the B cell subsets.
Resting naive B cells are epigenetically distinct in SLE. As expected, resting naive B cells from subjects with SLE and healthy controls expressed many hallmark B cell genes such as PAX5, IRF8, CD22, IL21R and CD19, and lacked expression of activation markers such as CD86 (Fig. 1d ,e and Supplementary Fig. 3 ), suggesting that core features of B cell development are not grossly altered by SLE. In healthy immune systems, resting naive cells represent the earliest unperturbed mature B cells available to mount primary immune responses. However, we have previously reported that resting naive B cells in SLE have distinct differences in accessible chromatin in comparison to cells at the corresponding stage from healthy controls 13 , indicating that the unique environment in SLE may alter the molecular machinery and properties of B cells conventionally defined as resting naive cells. Comparison of the epigenetic and transcriptional states of resting naive B cells from subjects with SLE and healthy controls revealed clear differences in each of the assays (Fig. 2a) . Correlation of the DNA methylation changes with gene expression identified a group of genes that were upregulated and demethylated in SLE B cells, including IFI44, PDCD1 and SPRY2 (Fig. 2b) . Additionally, a subset of genes were upregulated and contained DARs that had increased accessibility in resting naive B cells from subjects with SLE, including IFI44, STAT4, FOSL2, NR4A1, NR4A3 and SPRY2 (Fig. 2b-d and Supplementary Fig. 4 ). Expression of IFI44 is induced in SLE and in response to IFN 12 . Expression of NR4A3 and NR4A1 (Nur77) is induced in response to TLR stimulation 25 and signaling through the BCR 26 , respectively, suggesting that resting naive B cells in SLE may have received stimulation through these pathways. SPRY2 encodes a negative regulator of receptor tyrosine kinase (RTK) signaling 27 . Thus, these data indicate that resting naive B cells in SLE are epigenetically primed and distinct from their counterparts in healthy controls. Intriguingly, differences observed in resting naive B cells in SLE were also present in all the downstream B cell subsets (Fig. 2c,d) , suggesting that the SLE epigenetic B cell program is established as early as the resting naive stage. Notably, however, transcriptional upregulation of other gene sets at significant levels was only initiated at the activated naive stage and levels of regulation did not differ from those observed in control samples. This dichotomy was illustrated by two conventional activation markers: CD69 already highly overexpressed by resting naive B cells from subjects with SLE, whereas expression of CD86 was upregulated in activated naive B cells and peaked in DN2 cells (Supplementary Fig. 3 ). The second pattern was also found for other immunologically relevant genes, including TBX21 (encoding T-BET), ITGAX (encoding CD11c), AICDA ( Supplementary Fig. 5 ) and PDCD1 (encoding PD-1), with the latter two also suggesting BCR engagement. This pattern reflects a very high degree of overall transcriptional similarity between activated naive and DN2 cells. Together, these data suggest that there are unique and shared disease-specific features that may impact cellular differentiation in SLE.
DNA methylation stratifies cells from subjects with SLE and healthy controls. Analysis of DNA methylation profiles identified a distinct molecular SLE disease signature consisting of 6,664 DMLs that stratified all control and SLE samples (Fig. 3a) . DMLs were classified into three distinct modules by k-means clustering. CpGs in module 1 lost DNA methylation as the cells progressed through differentiation but were hypermethylated in all SLE B cells subsets as compared to their counterparts in healthy controls (Fig. 3b) . The mean CpG methylation for each cell type was quantified and revealed that SLE B cells were hypermethylated as compared to B cells from healthy controls. CpGs in modules 2 and 3 corresponded to subsets of DMLs that were hypo-and hypermethylated, respectively, in all SLE B cells. Because DNA methylation may provide a useful biomarker for disease, we identified the CpGs in modules 2 and 3 that best stratified SLE samples from healthy control samples regardless individuals' age, which is known to affect DNA methylation 28 . Using a minimum DNA methylation change of 40%, we identified 111 CpGs that stratified subjects by SLE status and included hypomethylated sites near the IFI44, IFITM1, YBX1 and TAF8 genes and hypermethylated CpGs surrounding SOX12, ARFGAP3, CCDC81 and MEG3 (Fig. 3c,d and Supplementary Table 2 ). EPSTI1, which encodes a positive regulator of NF-κB signaling 29 , is induced by IFN and is associated with SLE susceptibility 30 , had a highly predictive cluster of five CpGs in its first intron (Fig. 3e,f) . Each of the CpGs was hypomethylated and EPSTI1 expression was upregulated in all of the SLE B cell subsets (Fig. 3g) . To confirm these findings, we performed a quantitative PCR (qPCR) assay 18 on resting naive B cells from an independent cohort and found that CpGs at the EPSTI1, IFITM1 and MX1 loci were consistently demethylated in Table 5 . HC, healthy control; rN, resting naive; aN, activated naive; SM, switched memory. b, Mean CpG methylation for each cell type is plotted. Data represent mean ± s.d. Significance was determined by two-way analysis of variance (ANOVA) with Tukey's post-hoc test. *P < 0.05. c, Phylogenetic dendrograms for healthy control (top) and SLE (bottom) subsets for the indicated data. The length of tree branches between cell types corresponds to Euclidean distance, which is denoted for each tree with a scale bar. The reproducibility of tree structures was tested using a bootstrapping analysis and nodes that were less than 100% reproducible are represented by a yellow circle. Data were averaged for each cell type. d, Heat map of normalized enrichment score (NES) calculated by GSEA for pathways upregulated in cell types as compared to resting naive B cells. Healthy control and SLE B cells are separated and a subset of gene sets are grouped into common pathways. Pc, plasma cell. See also Supplementary Fig. 3 . e, Heat map of z score-normalized RPKM expression for selected genes from enriched GSEA gene sets. Data represent the mean expression for each cell type. subjects with SLE as compared to healthy controls (Fig. 3h) . Thus, clear differences in the DNA methylation patterns of B cells from subjects with SLE and healthy controls exist and identify DMLs that could be used as potential SLE biomarkers.
DN2 B cells in SLE have a distinct chromatin landscape from DN2 and isotype-switched memory B cells in healthy controls.
In the DNA methylation phylogenetic analysis, DN2 and isotypeswitched memory B cells were in a similar position with respect to their differentiation state and hierarchy. However, the PCA and phylogenetic analyses of accessible chromatin and gene expression datasets indicated that distinct differences existed between DN2 and isotype-switched memory cells. A comparison of DARs identified thousands of loci that were distinct between DN2 and isotypeswitched memory B cells in both SLE and healthy control samples (Fig. 4a) . Annotation of DARs to genes revealed that approximately 50% of the accessible chromatin in DN2 cells was shared by healthy controls and subjects with SLE with samples from both groups displaying uniquely accessible gene promoters or regulatory regions (Supplementary Table 3 ). Irrespective of disease status, a highly significant correlation was observed between DARs and DEGs for isotype-switched memory and DN2 B cells (Fig. 4b) , suggesting that events that generate DARs may influence gene expression. Moreover, direct comparison of DN2 B cells from subjects with SLE and healthy controls identified significant numbers of DARs and DEGs (Fig. 4c) . Therefore, DN2 B cells in SLE are distinct from DN2 and isotype-switched memory B cells in healthy controls.
Functional annotation of genes surrounding accessibility patterns in DN2 B cells, in comparison to isotype-switched memory B cells (from healthy control and subjects with SLE) was determined by Gene Ontology (GO) analysis. This identified genes involved in signaling from the TCR and BCR, signaling from co-stimulatory molecules and the response to lipopolysaccharide (Fig. 4d) . As described for ABCs 7, 8 and consistent with our initial functional and transcriptional results 6 , these data suggest that TLR stimulation may be unique to the differentiation history of DN2 B cells, a contention that is supported by the significantly lower expression of TRAF5, a negative regulator of TLR activation, in B cells, including in DN2 B cells 6, 31 . Additional genes associated with ABCs that were unique to both DN2 and activated naive B cells from healthy cotnrols and subjects with SLE (as compared to isotype-switched memory B cells) included TBX21, AICDA and GAS7 (Supplementary Fig. 5 ). We further characterized the similarity of DN2 B cells with previously published datasets from ABCs 8, 32 . DN2 B cells from both healthy controls and subjects with SLE displayed a significant enrichment of multiple ABC gene signatures 8, 32 ( Supplementary Fig. 6 ). However, no significant enrichment of ABC signatures was observed when comparing DN2 B cells from subjects with SLE to healthy controls, indicating that the signature is common to DN2 B cells irrespective of disease status. DN2 B cells also had unique accessibility patterns at the TNFRSF1B gene encoding the tumor necrosis factor (TNF) receptor and at ZAP70, which encodes a Src family protein tyrosine kinase that enhances BCR signaling and is highly expressed in individuals with chronic lymphocytic leukemia with poor clinical outcomes 33 . DN2 B cells from healthy controls were uniquely enriched for the distinct signaling pathways, transcriptional repression and regulation of the cell cycle ( Fig. 4d and Supplementary Fig. 3 ).
DN2 B cells from subjects with SLE were specifically enriched for genes associated with tyrosine kinase signaling as compared to isotype-switched memory B cells (Fig. 4d) . For example, FGFR1, and an absolute DNA methylation change greater than 40%. Significance was determined by two-sided t test with BenjaminiHochberg FDR correction. d, Violin plots of the percentage of DNA methylation across all B cell subsets for healthy control (n = 43) and SLE (n = 49) samples. Gray dots represent the mean and filled boxes represent first and third quartiles. e, Genome plot of the EPSTI1 locus showing the location of CpGs covered by RRBS. Significant DMLs between healthy control and SLE samples are boxed. Data represent the mean for each cell type from one experiment. f, Violin plots of the five CpGs highlighted in e across all B cell subsets for healthy control (n = 43) and subjects with SLE (n = 49). Gray dots represent the mean and filled boxes represent the first and third quartiles. g, Bar plots of gene expression levels for EPSTI1. Data are plotted as mean ± s.d. An asterisk indicates DEGs between SLE and healthy control samples (at least twofold change and FDR < 0.05) as determined by edgeR. h, qPCR of DNA methylation levels in resting naive B cells from an independent cohort of healthy controls (n = 9) and subjects with SLE (n = 9). Significance was determined by twotailed Student's t test.
which was upregulated in DN2 B cells in SLE, showed accessible chromatin peaks in DN2 B cells as compared to isotype-switched memory B cells ( Supplementary Fig. 5 ). The phosphorylation of specific tyrosine residues on TLRs by growth factor receptors such as epidermal growth factor receptor modulates downstream signaling events 34, 35 , suggesting that similar activation of FGFR1 or other tyrosine kinases may enhance TLR signaling in B cells in SLE. ITGAX, encoding a marker associated with ABCs 8 , was also highly upregulated in DN2 B cells from subjects with SLE and had unique accessible regulatory regions. Additionally, the PDCD1 promoter and cis-regulatory elements were highly accessible in DN2 B cells as compared to isotype-switched memory B cells and PDCD1 was upregulated at both the mRNA and protein levels in SLE B cell subsets (Fig. 4e-g ). Consistent with the phylogenetic analysis, highly similar patterns of gene expression and accessibility were observed for DN2 and activated naive B cells in SLE samples. For example, GAS7 was only expressed in activated naive and DN2 B cells. These data suggest a common epigenetic programming relationship between these cell subsets and a mechanistic link for their prominent expansion in active SLE.
DN2 B cell accessibility is programmed by T-BET, AP-1 and EGR transcription factors.
To identify the transcription factor networks driving the accessibility patterns in DN2 and isotypeswitched memory B cells, the DARs were searched for enriched transcription factor-binding motifs. Enriched motifs were grouped, revealing common and unique sets of motifs for accessible loci in DN2 and isotype-switched memory B cells. Shared motifs included those for lineage factors important for B cell identity, such as PU.1, RUNX1 and E2A as well as the ETS:IRF composite motif (Fig. 5a) . The top enriched motifs in DN2 B cells were for T-BET, ISGF3, and the AP-1 and EGR transcription factor families. T-BET and AP-1 motifs have been found to be enriched in the accessible chromatin of ABCs that accumulate in SWEF-familydeficient mice that develop systemic autoimmunity 9 . Conversely, loci in isotype-switched memory B cells were uniquely enriched for EBF, NF-κB and OCT motifs. In comparison to all other cell subsets, DN2 B cells had the highest levels of accessibility at T-BET, EGR-and AP-1 motifs (Fig. 5b and Supplementary Fig. 7 ). In line with the findings above, activated naive B cells also had high accessibility at these motifs with activated naive B cells from subjects with SLE displaying higher accessibility than activated naive B cells from healthy controls. For each of the three motifs, minimal accessibility was observed in T3, resting naive and isotype-switched memory B cells. In contrast, NF-κB motifs displayed the highest levels of accessibility in isotype-switched memory B cells and the lowest accessibility in activated naive and DN2 B cells. T-BET binding profiles from human B cells 36 displayed enrichment at loci accessible in activated naive and DN2 B cells at the GAS7, TNFRSF1B, ITGAX and ZAP70 loci (Fig. 5c and Supplementary Fig. 5 ). Interestingly the TBX21 locus, which encodes T-BET, also contained an upstream distal element that was bound by T-BET and showed enhanced accessibility in activated naive and DN2 B cells. Thus, isotype-switched memory and DN2 B cells express distinct transcription factors that correlate with unique accessibility patterns, transcription factor networks and gene expression programs.
Coordination of the SLE transcriptome and transcription factor signatures. For genes such as STAT4 (which harbors a major SLE 
Fig. 5 | Chromation accessibility in DN2 B cells is driven by T-BET, AP-1 and EGR transcription factors. a,
Heat map depicting normalized enrichment of transcription factor motifs in DN2 and isotype-switched memory B cell types. Enrichment P values were normalized to the minimum value for each cell type. Motif grouping is indicated on the left. Significance was determined by binomial distribution using HOMER. b, Histograms (left) and box plots (right) of accessibility at the indicated motifs and surrounding sequences for each cell type. Data represent the mean for each cell type. The locations of motifs are indicated for the histograms. In box plots, the center line indicates the median, the lower and upper bounds of boxes indicate the first and third quartiles and whiskers indicate the upper and lower limits of the data. Significance was determined by two-tailed Student's t test. See also Supplementary  Fig. 7 . c, Genome plots showing accessibility and T-BET binding in GM12878 B cells 36 for the indicated loci. DARs between DN2 and isotype-switched memory B cells with T-BET-binding peaks are boxed. Data represent the mean for each cell type from one experiment. risk allele 2 ) and IFI44, the expression and accessibility differences observed in resting naive B cells from subjects with SLE versus the corresponding cells in healthy controls were also shared among the other cell subsets, indicating the presence of a common SLE disease signature. Indeed, 5,090 DEGs were identified across all cell types (Fig. 6a) . GSEA identified pathways that were upregulated in all SLE B cells including gene sets related to the inflammatory, IFN-γ and IFN-α responses that have been previously identified in SLE samples 12 ( Fig. 6b and Supplementary Fig. 8 ). Additionally, we identified the WNT, Notch and estrogen signaling pathways, cytokine signaling from IL-6 and IL-2 receptors, and the p53 and apoptosis pathways as enriched in SLE B cells. By contrast, DN2 B cells from subjects with SLE showed negative enrichment for several pathways, including those driving the UPR and G2/M checkpoint.
Analysis of the SLE disease signature manifested in the accessible chromatin landscape identified thousands of SLE-specific DARs (Fig. 6c) . The PageRank algorithm 37 was used to identify transcription factor-binding motifs that correlated with changes in gene expression at target genes and to determine the overall importance of each transcription factor to the SLE transcriptional network. PageRank analysis identified 31 transcription factors that were enriched in three or more SLE B cell subsets as compared to their counterparts in healthy controls (Fig. 6d) . Genes encoding these factors were upregulated in SLE cells (for example, EGR4, AHR, JUN, JUND and FOSL1) (Fig. 6e and Supplementary Fig. 8) . However, some genes like BCL6 were expressed at the same level irrespective of disease status, indicating that the encoded factors may be recruited to unique targets genes in SLE B cells to which they are not recruited in HC B cells from healthy controls.
One of the highest scoring transcription factors was EGR4. EGR factors are transcriptionally upregulated in response to multiple cellular stimuli and have been implicated in autoimmunity, including in SLE 38 . RNA-seq suggested that all four members of the EGR family had upregulated expression in SLE B cells ( Supplementary  Fig. 8 ). To validate these findings, we performed qPCR coupled with reverse transcription (RT-qPCR) for each of the EGR family members in resting naive B cells from an independent cohort of subjects with SLE and healthy controls. Here we observed significant upregulation of EGR1 and EGR2 in resting naive B cells in SLE and minimal expression of EGR3 and EGR4 (Fig. 6f) , findings that are consistent with observations in other cohorts 6 . Moreover, we analyzed ENCODE chromatin immunoprecipitation with sequencing (ChIP-seq) data 36 for EGR1 and found a significant overlap of EGR1 peaks with SLE DARs (Supplementary Fig. 7 ). To demonstrate the importance of EGR factors to the disease transcriptional network, the target genes for each family member were mapped to GSEA gene sets from the DEG disease network. Importantly, genes predicted by network analysis to be regulated by EGR factors were enriched in 19 of the 22 gene sets (86%) upregulated in SLE (Fig. 6b,g ). The EGR factors also targeted other transcription factors, placing them at the apex of the disease network and further indicating the importance of these factors to the SLE transcriptional state. Analyzing the network for each of the factors showed a remarkable connectivity and overlap between the networks for EGR1 and ERG4 as compared to those for the other EGR factors, suggesting that the transcriptional differences in SLE are, in part, driven by EGR transcription factors. (Fig. 7a) . As described above, all four EGR family members were upregulated and highly enriched in the SLE DN2 B cell network. Additional significant regulators constituted the ATF/CREB family of factors, including CREM, CHOP (encoded by DDIT3) and ATF3. ATF3 is induced in response to BCR and TLR stimulation and cellular stress and can mediate the responses of p53 and various hormone receptors [39] [40] [41] . ATF3 was upregulated in all SLE B cell subsets, with maximal expression in SLE DN2 B cells (Fig. 7b) . To validate these findings, we quantified ATF3 mRNA levels in resting naive B cells by RT-qPCR and found that ATF3 was significantly upregulated in resting naive B cells from SLE samples as compared to healthy control samples (Fig. 7c) . Consistent with mRNA levels, ATF3 protein was more abundant in resting naive, activated naive, isotypeswitched memory and DN2 B cell subsets from subjects with SLE as compared to healthy controls (Fig. 7d,e) . Using the predicted target genes from the PageRank analysis, we identified 98 ATF3 target genes that were disease DEGs, of which 87% were upregulated in SLE (Fig. 7f and Supplementary Table 4) . DNA footprinting analysis revealed a large difference at ATF3 motifs and the surrounding chromatin in SLE B cells as compared to B cells from healthy controls (Fig. 7g) . Quantification of accessibility of the ATF3 motif in each cell subset identified SLE DN2 B cells as having the highest levels of accessibility (Fig. 7h) . Additionally, ATF3 peaks identified by ChIP-seq 36 significantly overlapped SLE DARs ( Supplementary  Fig. 7 ). ATF3 heterodimerizes with Jun family members 40 , of which three (JUN, JUNB and JUND) were enriched in the DN2 networks and upregulated in SLE (Fig. 7a and Supplementary Fig. 8 ). Additionally, for these ATF3 motifs we did not find any co-occurrence with IRF4 in the context of AICE composite motif 42 , and only 7 of the 98 genes (7%) were predicted to be regulated by IRF4 by PageRank. ATF3 target genes were mapped to functional gene sets enriched in SLE samples and found to have roles in cell cycle and metabolism through the MTORC1 pathway, G2/M checkpoint, TNF signaling, hypoxia, UPR and apoptosis (Fig. 7i) . Thus, ATF3 and EGR together with their respective family members regulate DN2-specific B cell transcriptional pathways that are important for SLE epigenetic programming.
Discussion
Here we used an integrated transcriptional and epigenetic approach to unravel the nature of B cell populations, their differentiation hierarchy and the molecular programs that underpin their abnormal behavior in SLE. We focused on finely discriminated subsets, representing the human extrafollicular naive B cell differentiation pathway responsible for the generation of DN2 cells 5, 6 . Our analysis was performed on an African-American cohort with high disease activity. Going forward it will be important to determine how these epigenetic programs evolve during the progression of SLE, in quiescent versus active disease, and whether this epigenetic imprint exists in other ancestry groups.
The data suggest a differentiation order with T3 and activated naive cells being derived from activation of resting naive cells with DN2 and isotype-switched memory B cells placed further down the differentiation path to ASCs. T3 cells have been previously defined as transitional cells in human studies of repopulating B cells after rituximab treatment 43 . Our study suggests that in active SLE T3 cells represent an early phase of naive B cell activation. In SLE, consistent with their phenotypic similarity 6 , activated naive and DN2 B cells shared features of accessible chromatin, were transcriptionally related to each other, yet distinct from the other three B cell subsets; and were closer to ASCs than to any other subset, including isotypeswitched memory B cells. In combination, these data support the notion that DN2 B cells represent a distinct effector subset that is expanded in SLE. Our results are also consistent with separate differentiation pathways in which ASCs are derived from either activated naive-DN2 cells or isotype-switched memory cells.
Consistent with our initial findings 13 , resting naive B cells in subjects with SLE were distinctly primed at an early differentiation stage. That some of the SLE transcriptional and epigenetic signatures were shared by all SLE B cell subsets demonstrates that SLE B cells are under the control of a unique transmissible epigenome that regulates the effect of the SLE environment on all mature B cells and modulates their activation threshold. Elucidating the earliest stage of development at which B cell precursors may be epigenetically modified in SLE could guide optimization of B cell therapies.
Analysis of changes in epigenetic modifications identified programs responsible for the abnormal behavior of individual B cell subsets in SLE and, in particular, programs associated with extrafollicular effector cells. The accessible chromatin of DN2 B cells was specifically enriched for T-BET, EGR and AP-1 transcription factor motifs. Our data provide insight into a T-BET-driven program that is shared by healthy control and SLE DN2 B cells. T-BET was upregulated in DN2 B cells irrespective of disease status, was enriched in DN2-specific accessible chromatin, and regulated other markers characteristic of ABCs and DN2 cells, such as CD11c. Moreover, T-BET bound to its own gene, suggesting that it may function in an autoregulatory manner in these cells. This indicates that DN2 B cells are a normal product of B cell differentiation, but in abnormal immune environments, such as in SLE, their formation is enhanced and/or their presence is sustained, and they may harbor additional properties based on their unique disease-specific transcriptome and epigenomes.
We previously postulated a developmental link between activated naive and DN2 B cells and ASCs in SLE 6 . This model is supported by the fact that activated naive and DN2 B cells in SLE share distinct epigenetic and transcriptional profiles and have close relationships in phylogenetic trees. This close relationship was mirrored for many genes, such as ITGAX, GAS7 and PDCD1. Additionally, the enhanced accessibility of core SLE AP-1 and EGR transcription factor motifs was present in activated naive cells (relative to resting naive and T3 cells) and increased further in DN2 cells, but was largely absent in isotype-switched memory B cells. Thus, these data provide a mechanistic link between dysregulation of central SLE networks and transcription factors and the skewing of B cell differentiation towards the activated naive-DN2 cell fate.
An informative example of the SLE programs shared across B cell populations that are already engaged in resting naive cells is illustrated by the NR4A family of nuclear receptors. NR4A1 is induced specifically by BCR stimulation 26 , while NR4A2 and NR4A3 are induced in response to TLR stimulation 25 . This is consistent with mouse lupus models induced by BCR and TLR co-stimulation leading to tolerance breakdown 44 and our previous data showing that activated naive and DN2 B cells are hyperresponsive to TLR7 stimulation and contain clonally expanded autoreactive B cells 5, 6 . Of note, DN2 B cells demonstrated unique chromatin accessibility patterns surrounding BCR and TLR signaling components, suggesting that initial engagement of both these pathways in naive B cells may be propagated to later stages of differentiation. These data fit a model of autoimmunity in which BCR and TLR signals can converge in extrafollicular settings to stimulate and expand autoreactive B cells 4, 44, 45 . Our data indicate that in SLE, resting naive B cells are subjected to positive antigenic stimulation and therefore provide an important window to understand early antigenic triggers in SLE.
The expression of ATF/CREB, AP-1 and EGR family transcription factors was maximally enriched in the DN2 subset in SLE. EGR proteins have been linked to autoimmunity, are induced by BCR stimulation 46 and regulate plasma cell differentiation 47, 48 . EGR1 was highly induced in SLE in multiple cohorts and demonstrated connectivity to many dysregulated transcriptional networks. Similarly, ATF3 was highly enriched in the DN2 B cell network. Each of these factors was predicted to impact metabolism, cell cycle, apoptosis and the response to cellular stress. The upregulation of oxidative phosphorylation enhances plasma cell differentiation 49 . Interestingly, the G2/M checkpoint and apoptosis pathways were induced in all SLE B cell subsets except DN2 B cells, which might explain their expansion in SLE. These data suggest that the balance between pathways that promote or oppose differentiation may be altered in SLE DN2 B cells. Mechanistically, this may occur by switching transcription factor partners. ATF3 for example, functions as a repressor when bound as a homodimer but can heterodimerize with Jun family members to function as an activator 40, 41 . The coordinated upregulation of Jun family members with ATF3 suggests that the equilibrium of ATF3 activity shifts toward activation in SLE, particularly in the DN2 B cell subset. Moreover, the main T-BET inducer, IFN-γ, can synergize with TLR stimulation to enhance the expression of ATF3 (ref. 50 ). Thus, the coordination of stimuli with known pathogenic relevance may offer a mechanistic link between molecular and cellular abnormalities in SLE. SLE B cell subsets had higher overall levels of DNA methylation than their counterparts in healthy controls. This may reflect more recent differentiation from a highly methylated progenitor B cell 20 . Alternatively, the SLE program may depend on the maintenance of methylation at the loci observed. Nonetheless, while the DNA methylation patterns did not specifically identify disease pathways, the presence or absence of DNA methylation at different loci could potentially serve as biomarkers of disease and disease progression as illustrated by 111 CpGs that discriminated between SLE and healthy control B cells. As these differential DNA methylation modifications occurred in all B cell subsets, including in resting naive B cells, it is not known when such modifications are first imprinted into the SLE epigenome and these modifications may represent an epigenetic record of differentiation history and disease state.
In summary, we have defined the transcriptomes and epigenomes of B cell subsets that are expanded in SLE. Our data indicate a disease signature across all cell subsets, and importantly, in mature resting B cells, suggesting that such cells may have been exposed to disease-inducing signals. Together, these data define the imprint of SLE on the epigenome of specific B cell populations and highlight transcription factor networks and programming of normal and pathogenic B cells subsets.
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Methods
Human subjects. Four independent cohorts were used for this study and are detailed in Supplementary Table 1 . Whole-blood samples were obtained with informed consent from all participants in accordance with Emory University School of Medicine Institutional Review Board protocols.
Flow cytometry isolation of human B cell subsets. Whole blood (50-100 ml) was isolated from each subject via venous puncture utilizing cell preparation tubes containing sodium heparin and Ficoll-Hypaque solution (Becton Dickinson). Washed PBMCs were resuspended in 1 ml of prewarmed complete medium (RPMI 1640, 10% FBS and 1% l-glutamine) containing 20 nM of MTG and incubated at 37 °C in 5% CO 2 for 30 min. Next, PBMCs were centrifuged at 1,300 r.p.m. for 10 min at room temperature, resuspended in 10 ml of prewarmed complete medium and incubated at 37 °C in 5% CO 2 for 30 min to allow for excess MTG to be pumped out of B cells possessing the ABCB1 transporter 17 . PBMCs were centrifuged at 1,300 r.p.m. for 10 min at 4 °C and resuspended at 10 7 PBMCs per 100 μl in PBS with 0.5% BSA, 5% normal mouse serum and 5% normal rat serum containing the following fluorochrome-conjugated human-specific monoclonal antibodies: anti-CD3 and anti-CD24 (Invitrogen); and anti-CD19, anti-IgD, anti-CD27 and anti-CD38 (BD Biosciences). Cells were incubated in the dark for 30 min at 4 °C, washed with 5 ml of PBS and centrifuged at 1,300 r.p.m. for 10 min at 4 °C. PBMCs were resuspended in 1 ml of PBS and subjected to live/dead Aqua staining (Invitrogen) according to the manufacturer's protocol. Following live/ dead incubation, PBMCs were washed in 5 ml of PBS containing 0.5% BSA and centrifuged at 1,300 r.p.m. for 10 min at 4 °C. Pelleted PBMCs were resuspended in 1 ml of prewarmed complete medium and filtered using a prewetted 35-μm cell strainer FACS tube (Corning). B cell subsets were purified using a FACS Aria II. To ensure sort purity, the FACS Aria II was calibrated to 99.9% purity using fluorescent beads before each sort.
Quantification of PD-1 and ATF3 expression. PBMCs were isolated as described above and stained in the presence of 10% normal mouse serum with the following fluorochrome-conjugated antibodies: anti-CD19, anti-CD27, anti-CD38 and antiIgD (BD Biosciences) and anti-CD11c, anti-CD3, anti-CXCR5 and anti-CD279 (PD-1) (BioLegend). For intracellular staining, cells were fixed, permeabilized and stained using the Tru-nuclear Transcription Buffer set (BioLegend). Cells were blocked with 50 μg ml −1 rabbit IgG and stained with 2 μg ml −1 rabbit anti-human ATF3 (USBIO) or rabbit IgG isotype control (Invitrogen). Single-color-stained anti-mouse Ig beads (Bangs) were used as compensation controls. Flow cytometry data were collected with BD FACSDiva v.6.2 and data analysis was performed in FlowJo (TreeStar) v.10.4.
RNA sequencing. RNA from sorted cell populations was isolated using the AllPrep DNA/RNA Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA (50 pg) was used as input for the SMART-seq v3 cDNA synthesis kit (Takara) using ten cycles of PCR amplification. cDNA (1 ng) was used as input for the NexteraXT kit (Illumina) using nine cycles of PCR amplification. Final libraries were quantified by qPCR and size distribution was determined by Bioanalyzer before pooling and sequencing on a HiSeq2500 using 50-bp paired-end chemistry.
RNA sequencing data analysis. Raw fastq files were mapped to the hg19 version of the human genome using TopHat2 v.2.0.13 (ref. 51 ) with the default parameters and the UCSC KnownGene reference transcriptome 52 . Duplicate reads were removed with PICARD v.1.127 (http://broadinstitute.github.io/picard/). For all unique ENTREZ genes, the coverage at each exon was summarized using custom R and Bioconductor scripts and the GenomicRanges v.1.22.4 package 53 and normalized to reads per kilobase per million reads (RPKM). Genes were filtered for detection on the basis of being expressed at greater than 3 reads per million in all samples for at least one group (that is, healthy control resting naive or SLE DN2 B cells). Differential gene expression for detected genes was determined using edgeR v.3.18.1 (ref. 54 ) and a generalized linear model. To determine disease differences covariates included patient and cell type; for cell type differences covariates included disease status and patient. Genes with a greater than twofold change and FDR < 0.05 in comparisons were termed significant. To generate heat maps the RPKM values for all detected genes were quantile normalized and then select genes for plotting were z score normalized. For GSEA all detected genes were ranked by multiplying the direction of the fold change (that is, positive or negative) by the −log 10 P value from edgeR. The resulting list was used as input for the PreRanked analysis in GSEA v.3.0.
ATAC-seq. ATAC-seq 13 was performed by resuspending 1,000-20,000 flow cytometry-sorted cells in 50 μl of nuclei lysis buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl 2 and 0.1% IGEPAL CA-630) and centrifuging at 500g for 30 min at 4 °C. Next, the supernatant was removed and cells were resuspended in 25 μl tagmentation mix (300 mM NaCl, 100 mM EDTA, 0.6% SDS and 1.6 μg proteinase-K) and placed in a thermocycler at 37 °C for 1 h. Cells were lysed and high-molecular-weight DNA was removed using 0.6× SPRI-bead negative selection and low-molecular-weight DNA was purified by 1.2× SPRI-bead positive selection. The resulting tagmented DNA was PCR amplified and indexed using Nextera Indexing primers (Illumina) and 2× HiFi Hotstart Ready Mix (Roche). Following PCR, high-molecular-weight DNA was removed using 0.3× SPRI-bead negative selection and low-molecular-weight DNA was purified by 1× SPRI-bead positive selection. Final libraries were checked for ATAC-seq specific patterning on a Bioanalyzer and quantified by qPCR before pooling at equimolar ratios and sequencing on a HiSeq2500 using 50-bp pairedend chemistry.
ATAC-seq data analysis. Raw fastq files were mapped to the hg19 version of the human genome using Bowtie v.1.1.1 (ref. 55 ) with the default parameters and duplicate reads were removed with PICARD v.1.127 (http://broadinstitute. github.io/picard/). Accessible peaks of enrichment were called using MACS2 v.2.1 (ref. 56 ) with the default parameters. A unified set of peaks found in one or more samples was created using the mergePeaks.pl function in HOMER v.4.8.2 (ref. 57 ) and the raw read count for each peak was annotated for each sample using the GenomicRanges v.1.22.4 package (ref. 53 ). The resulting data were reads per peak per million (RPPM) normalized for the fraction of reads in peaks 58 and sequencing depth as previously described 13 . DARs were identified using edgeR v.3.18.1 (ref. 54 ) and a generalized linear model. To determine disease differences covariates included patient and cell type; for cell type differences covariates included disease status and patient. Peaks with a greater than twofold change and FDR < 0.05 in comparisons were termed significant. To identify motifs enriched in DARs, the findMotifsGenome.pl function of HOMER v.4.8.2 (ref. 57 ) and the 'de novo' output were used for downstream analysis. For the motif heat map analysis the enrichment P value for each motif was normalized to the maximum P value in each cell type. To generate motif footprints the motifs occurring in peaks were annotated with the HOMER v.4.8.2 (ref. 57 ) annotatePeaks.pl function using the option '-size given' . Next, the read depth at the motif and surrounding sequence was computed using the GenomicRanges v.1.22.4 package 53 and custom scripts in R and Bioconductor and the coverage at each base was plotted as a histogram or summarized as a box plot. GO biological process enrichment analysis of DARs was performed using DAVID 59 . The resulting list of GO terms was filtered using REVIGO 60 to generate a list of terms containing unique sets of genes.
Reduced-representation bisulfite sequencing. DNA was isolated from the same fraction as RNA using the AllPrep DNA/RNA Mini kit (Qiagen) according to the manufacturer's instructions. A dual-restriction enzyme RRBS assay 18 was performed by splitting the DNA into two aliquots and digesting over night with either MspI or TaqI (NEB). The resulting DNA was purified and digestion efficiency was quantified by qPCR using primers spanning sequences that contained one, both or no restriction site. For bisulfite conversion controls, ΦX174 phage DNA (NEB) was in vitro methylated with M.SssI methylase (NEB). Methylated ΦX174 phage DNA and unmethylated lambda phage DNA (NEB) were sonicated to generate random 200-to 400-bp fragments. Each DNA (10 pg, 1:10,000 ratio of phage to genomic DNA) was spiked into the purified digested genomic DNA to use as a bisulfite conversion control. Sequencing adaptors were ligated using the HyperPrep kit (KAPA Biosystems) and fully methylated short adaptors 61 . Adaptor-ligated DNA was bisulfite converted using the EpiTect Bisulfite kit (Qiagen) according to the manufacturer's protocol except that the denaturation temperature was increased to 99 °C for 10 min. Final libraries were PCR amplified with custom indexed primers and HiFi Uracil and polymerase (KAPA Biosystems). The resulting RRBS library was quality checked by Bioanalyzer, quantified by qPCR, pooled at equimolar ratio and sequenced on a HiSeq2500 using 50-bp paired-end chemistry.
RRBS data analysis. Raw fastq files were mapped to a composite genome index containing hg19, ΦX174 and lambda phage genomes using Bismark v.0. 16.3 (ref. 62 ). CpG calls were determined using the Rsamtools v.1.22.0 and data.table v.1.10.4.3 packages and custom R scripts as previously described 18 . All CpGs with at least 10× coverage per group (9,803,151) were determined and differential methylation analysis was performed using the DSS v.2.10.0 package 63 and a generalized linear model. To determine disease differences, covariates included patient and cell type; for cell type differences, covariates included disease status and patient. CpGs with FDR < 0.05 and a difference in methylation greater than 20% in comparisons were called significant. k-means clustering of the disease DMLs was performed using the Biganalytics package (https://CRAN.R-project.org/ package=biganalytics). To determine predictive CpGs from modules 2 and 3, we built a linear regression model at each CpG to find associations between SLE status and DNA methylation using a two-sided t test with age as a covariate. The resulting P values were FDR corrected using the Benjamini-Hochberg method and CpGs with a minimum change of 40% between healthy controls and subjects with SLE and FDR < 5 × 10 −8 were considered highly predictive.
Meta-analysis.
For PCA and phylogenetic analysis, all significant differences (DMLs, DEGs and DARs) for comparisons between all cell types were selected pairwise and the data were z score normalized. PCA was performed using the vegan v.2.4-3 package in R and Bioconductor. Phylogenetic analysis was performed by computing a Euclidean distance matrix between samples, which
